July 19, 2012 07:30 ET

Four BioTech Companies Making Moves: EliteOTC Highlights (NASDAQ: STEM), (NASDAQ: SOMX), (NASDAQ: GALE), (OTCBB: ACTC)

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - Jul 19, 2012) - EliteOTC, the leader for breaking information and up-to-date market activities in North America's speculative markets, locates high-growth equity opportunities or equities with unrealized value to keep investors one step ahead of the crowd. Today EliteOTC is focusing on four small cap companies: StemCells Inc. (NASDAQ: STEM), Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), Galena Biopharma, Inc. (NASDAQ: GALE) and Advanced Cell Technology (OTCBB: ACTC).

StemCells Inc. (NASDAQ: STEM)

StemCells Inc. closed Wednesday's trading session at 1.50 following a heavy day of volume in which 11,067,114 shares moved hands. Investors are still buzzing over Tuesday's news in which STEM announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease (AD).

That news sent shares from an opening of 1.08 to 1.82, a level that was later eclipsed on Wednesday when they hit 1.84. At their current level shares are well above the 50-day moving average of 0.810 and their 200-day moving average of 1.160.

For a free report and detailed analysis visit:

Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX)

One day after reporting that they had secured market exclusivity for their insomnia treatment Silenor shares of Somaxon Pharmaceuticals more than doubled their Tuesday high before closing the day at 0.43. Shares hit 0.600 on Wednesday thanks in large part to SOMX announcing they would hold that market exclusivity till 2020.

With shares at their current level SOMX is comfortably ahead of their 50-day moving average of 0.290 and drawing nearer to their 200-day moving average of 0.560.

For a free report and detailed analysis visit:

Galena Biopharma, Inc. (NASDAQ: GALE)

Following news that Galena Biopharma, Inc. was issued a key patent covering the use of its product candidate, NeuVax™, a HER2/neu peptide vaccine, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC levels of 1+ or 2+ and a FISH rating of less than 2.0 shares in the biotechnology company skyrocketed, hitting a high of 2.30 before closing the day's session at 1.95.

Investors obviously responded favorably to the patent issuance coming from the U.S. Patent and Trademark Office (USPTO) as trading volume hit the 21,808,010 mark. At the current share price GALE is well ahead of their 50-day moving average of 1.450 and their 200-day moving average of 1.130.

For a free report and detailed analysis visit:

Advanced Cell Technology (OTCBB: ACTC)

Advanced Cell Technology continues to see strong activity one week after announcing treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD). Shares of ACTC closed Wednesday's session at 0.080, down slightly from their opening of 0.0840.

Despite the positive news shares of ACTC are only slightly ahead of their 50-day moving average of 0.0731 and a distance from their 200-day moving average of 0.09890.

For a free report and detailed analysis visit:

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid IO NewsWire one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.

Contact Information